High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease

American Heart Journal

Volumn 144, Issue 6 SUPPL., 2002, Pages

  Gotto Jr , Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; AVASIMIBE; BILE ACID CONJUGATE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOLIPASE A2; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; RETINOID; RETINOID X RECEPTOR; SERUM AMYLOID A; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL RESEARCH; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CORONARY ARTERY DISEASE; COVARIANCE; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EDUCATION PROGRAM; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036915240     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.130301     Document Type: Conference Paper

References (67)

1. Plutzky J. Emerging concepts in metabolic abnormalities associated with coronary artery disease. Curr Opin Cardiol 2000;15:416-21.
2. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part I. Circulation 2001;104:2376-83.
3. Gordon DJ, Rifkind BM. High-density lipoprotein - The clinical implications of recent studies [review]. N Engl J Med 1989;321:1311-6.
4. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-8.
5. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. JAMA 2001;285:1585-91.
6. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86(Suppl):19-22L.
7. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
8. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-51.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
10. Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-84.
11. Pedersen TR, Olsson AG, Færgeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
12. Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220-5.
13. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2002;25(Suppl 1):S74-7.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Educotion Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
15. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36.
16. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-84.
17. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943-9.
18. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
19. Miller M, Seidler A, Moalemi A, et al. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998;31:1252-7.
20. Castelli WP. The triglyceride issue: A view from Framingham. Am Heart J 1986;112:432-7.
21. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14:1767-74.
22. Malloy MJ, Kane JP. A risk factor for atherosclerosis: Triglyceride-rich lipoproteins. Adv Intern Med 2001;47:111-36.
23. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease: Implications for treatment. Arch Intern Med 1992;152:28-34.
24. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): A new look. Int J Cardiol 2000;74:S17-22.
25. Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: Further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000;86(Suppl):23-7L.
26. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.
27. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment. Circulation 1992;85:37-45.
28. Stein EA, et al. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81:66-9B.
29. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-8.
30. van der Wal AC, Becker AE, van der Loos CM, et al. Fibrous and lipid-rich atherosclerotic plaques are part of interchangeable morphologies related to inflammation: A concept. Coron Artery Dis 1994;5:463-9.
31. Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein lost its anti-inflammatory properties during acute influenza A infection. Circulation 2001;103:2283-8.
32. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
33. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
34. Libby P, Egan D, Skarlator S. Roles of infectious agents in atherosclerosis and restenosis. Circulation 1997;96:4095-103.
35. Jousilahti P, Vartiainen E, Tuomilehto J, et al. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996;348:567-72.
36. Meier CR, Jick SS, Derby LE, et ol. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998;351:1467-71.
37. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001;21:542-7.
38. Oda MN, Bielicki JK, Ho TT, et al. Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 2002;290:921-7.
39. 2 with a catalytic triad. J Biol Chem 1995;270:25481-7.
40. Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low-density lipoprotein. J Biol Chem 2001;276:44444-9.
41. Artl A, Marsche G, Lestavel S, et al. Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000;20:763-72.
42. Krause BR, Auerbach BJ. Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr Opin Investig Drugs 2001;2:375-81.
43. Ashby D, Gamble J, Vadas M, et al. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. Atherosclerosis 2001;154:113-21.
44. Steinmetz A, Hocke G, Saile R, et al. Influence of serum omyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989;1006:173-8.
45. 2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism. J Lipid Res 2000;41:1849-57.
46. 2: Preferential hydrolysis of acute phase HDL. J Lipid Res 1998;39:2150-60.
47. Ballantyne C, Houri J, Notarbartolo A, et al. Ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2002;39(A Suppl):227A.
48. Davidson M, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in 668 patients with primary hypercholesterolemia [abstract]. J Am Coll Cardiol 2002;39(A Suppl):226-7A.
49. Katsuren K, Tamura R, Arashiro R, et al. Structure of the human acyl-Co-A:cholesterol acyltransferase-2 (ACAT-2) gene and its relation to dyslipidemia. Biochim Biophys Acta 2001;1531:230-40.
50. Bocan TMA, Krause BR, Rosebury WS, et al. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 2000;20:70-9.
51. Insull W Jr, Koren M, Davignon J, et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001;157:137-44.
52. Repa JJ, Turley SD, Lobaccaro J-MA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000;289:1524-9.
53. Mukherjee R, Strasser J, Jow L, et al. RXR agonists activate PPARα-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arteriosder Thromb Vasc Biol 1998;18:272-6.
54. Nanjee MN, Brinton EA. Very small apolipoprotein A-1-containing particles from human plasma: Isolation and quantification by high-performance size-exclusion chromatography. Clin Chem 2000;46:207-23.
55. Hayek T, Azrolan N, Verdery RB, et al. Hypertriglyceridemia and cholesteryl ester transfer protein interoct to dramatically alter high density lipoprotein levels, particle sizes, and metabolism: Studies in transgenic mice. J Clin Invest 1993;92:1143-52.
56. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7.
57. Barroso I, Gurnell M, Crowley VE, et al. Dominont negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-3.
58. Marcus SL, Miyata KS, Rachubinski RA, et al. Transactivation by PPAR/RXR heterodimers in yeast is potentiated by exogenous fatty acid via a pathway requiring intact peroxisomes. Gene Expr 1995;4:227-39.
59. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72.
60. Gervois P, Torra IP, Fruchart JC, et al. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000;38:3-11.
61. Marx N, Sukhova GK, Collins T, et al. PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99:3125-31.
62. Spiegelman BM. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
63. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-9.
64. Marx N, Bourcier T, Sukhova GK, et al. PPAR-γ activation in human endothelial cells increases plasminogen activator inhibitor typed expression. PPAR-γ as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999;19:546-51.
65. Tontonez P, Nagy L, Alvarez JG, et al. PPAR-γ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52.
66. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 2001;107:1423-32.
67. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989;79:8-15.